Dennis Ruff

Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes

Brian Zambrowicz, Zhi‐Ming Ding, Ike Ogbaa et al. · Clinical Therapeutics · 2013 · 77 citations

Metabolic Syndrome, Diabetes Management, Diabetes +8

Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects

Brian Zambrowicz, Ike Ogbaa, Kenny Frazier et al. · Clinical Therapeutics · 2013 · 65 citations

Metabolic Syndrome, Molecular Pharmacology, Healthy Subjects +10

Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid

Graham Scott, Christiane Rordorf, Christine Reynolds et al. · Clinical Pharmacokinetics · 2004 · 59 citations

Synovial Fluid, Medicine, Local Pharmacology +3

A randomized, placebo‐controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers

Dennis Ruff, David Crockford, Gino Girardi et al. · Annals of the New York Academy of Sciences · 2010 · 45 citations

Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension

Dennis Ruff, Lisa P. Gazdick, Rayanne S. Berman et al. · Journal of Hypertension · 1996 · 35 citations

Blood Pressure Monitoring, Non-pharmacological Intervention, Hypertension +13